semaglutide oral cardiovascular indication news 2025 and Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial ACC 2025: Oral Semaglutide Reduces

both governments and academic institutions have initiated public consultation processes to pave the way for potential legislative legalisation

Influenza and Immune Function One placebo-controlled clinical study found that 600 mg of NAC taken twice daily during flu season (October through April) did not prevent influenza infection but significantly reduced symptom severity

This high-risk population will allow the trial to evaluate whether semaglutides metabolic and weight-loss effects can translate into meaningful reductions in cardiovascular events across different subgroups

Laffont, S

Medical records analysis showed that about 1.5 percent of non-diabetic men taking semaglutide had erectile dysfunction (ED)more than men who didnt take the weight-loss drug